The PHARM Connect Congress 2011

9-10 February 2011, Budapest, Hungary.
The PHARM Connect Congress 2011, an event organised by The Events Group, offers the perfect setting for solution providers to present their products and services directly to key decision makers of target client population throughout Central & Eastern Europe.

Strictly operating on an invitation only basis guarantees that the highest level of delegation is present. Each solution provider at the PHARM Connect Congress is selected based on requirements and interests provided by attending Pharmaceutical professionals prior to the Congress event.

Over two days, service providers will meet and interact with the leading director and C level practitioners through a number of pre-arranged one-to-one business meetings and other networking activities.

Several weeks in advance of the Congress, the TEG Meeting Scheduler is made available to all solution providers and delegates attending. Participants receive individualized passwords to access the website where they are able to select key presentations, pre-schedule one-to-one meetings and confirm their presence at several additional networking activities. Through the Meeting Scheduler, attendees have the opportunity to create their own itinerary prior to the Congress taking place.

This networking event presents a unique opportunity to develop meaningful and valuable business relations.

For further information and registration, please visit:
http://www.pharmconnect.eu

About The Events Group
The Events Group is one of Europe's leading business information providers. With two main areas of focus, business-to-business Congresses and Professional Training, we primarily operate within key emerging markets: Central & Eastern Europe.

Our unique business-to-business Congresses bring together senior-level executives from Europe’s largest organisations with a select and diversified group of leading edge sponsors. Strictly operating on an invitation only basis guarantees that the highest level of delegation is present.

Most Popular Now

GSK reaches agreement with Novartis to acquire ful…

GlaxoSmithKline plc (LSE/NYSE: GSK) today announces that it has reached an agreement with Novartis for the buyout of Novartis' 36.5% stake in their Consumer Healthcare Jo...

Canadian neuroscientists say daily ibuprofen can p…

A Vancouver-based research team led by Canada's most cited neuroscientist, Dr. Patrick McGeer, has successfully carried out studies suggesting that, if started early enou...

First proof a synthesized antibiotic is capable of…

A "game changing" new antibiotic which is capable of killing superbugs has been successfully synthesised and used to treat an infection for the first time - and could lea...

Merck partners with Medisafe to help improve medic…

Merck, a leading science and technology company, today announced a new collaboration with US-based Medisafe to help its cardiometabolic patients better manage medication ...

Phase III data in The Lancet show Novartis siponim…

Novartis today announced that the full results from the Phase III EXPAND study of oral, once-daily siponimod (BAF312) in secondary progressive multiple sclerosis (SPMS) w...

Taking a standard prostate cancer drug with food b…

By taking a high-cost drug with a low-fat meal - instead of on an empty stomach, as prescribed - prostate cancer patients could decrease their daily dose, prevent digesti...

New immunotherapy for lung cancer shows promise of…

In a groundbreaking development, results from a recent clinical trial to treat lung cancer show that a novel immunotherapy combination is surprisingly effective at contro...

Boehringer Ingelheim and OSE Immunotherapeutics an…

Boehringer Ingelheim and OSE Immunotherapeutics, a biotechnology company focused on the development of innovative immunotherapies, have announced a collaboration and excl...

Personalized tumor vaccine shows promise in pilot …

A new type of cancer vaccine has yielded promising results in an initial clinical trial conducted at the Perelman School of Medicine at the University of Pennsylvania and...

New targeted therapy schedule could keep melanoma …

Skin melanoma, a particularly insidious cancer, accounts for the vast majority skin cancer deaths and is one of the most common cancers in people under 30. Treatment for ...

Researchers identify chemical compound that inhibi…

An organic chemical compound shows effective antiviral activity against Ebola virus and several other viruses, according to a study led by Georgia State University. The r...

When drugs are wrong, skipped or make you sick: Th…

Rising drug prices have gotten a lot of attention lately, but the actual cost of prescription medications is more than just the dollars and cents on the bill. Researchers...